Metabolomic Signatures of Disease Severity in Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disorder characterized by immune-mediated injury to myelin, axons, and supporting glial cells within the central nervous system. Although clinical relapses, magnetic resonance imaging, and the Expanded Disability Status Scale (EDSS) remain central to disease monitoring, these measures do not fully capture the molecular processes that precede or accompany neurological deterioration. Villoslada and colleagues investigated whether serum metabolomics—the systematic measurement of small molecules generated by cellular and biochemical processes—could reveal molecular signatures associated not only with the presence of MS but also with disease activity and disability progression. Their study addresses a major objective in precision neurology: the identification of accessible biomarkers that can stratify patients according to biological disease severity and potentially support earlier therapeutic decisions. By examining hormones, amino acids, fatty acids, and several classes of complex lipids, the researchers sought to determine whether chronic neuroinflammation and tissue injury produce a detectable metabolic imprint in peripheral blood.
A Two-Cohort Strategy for Biomarker Discovery and Validation
A principal strength of the investigation was its use of two independent and clinically characterized patient cohorts. The larger retrospective longitudinal cohort included 238 patients with MS and 74 matched healthy controls recruited from five Spanish centers, while the prospective cohort included 61 patients and 41 controls who underwent repeated serum sampling during two years of observation. Clinical information—including relapses, disease subtype, treatment exposure, disease duration, and EDSS scores—was collected longitudinally. Patients were subsequently classified as having stable or active disease according to relapse frequency or confirmed disability worsening. The investigators also compared individuals with relatively mild disability, defined by an EDSS score below 3.0, with those reaching more substantial disability, defined by an EDSS score above 4.5. This dual-cohort design served two complementary purposes: the prospective cohort permitted evaluation of the temporal stability of metabolic signals, whereas the larger multicenter cohort provided greater statistical power and allowed specific metabolites to be identified and tested across a more heterogeneous clinical population.
Mass Spectrometry and Multivariate Classification
Serum metabolites were analyzed using ultra-high-performance liquid chromatography coupled to mass spectrometry, or UHPLC-MS. In the prospective cohort, the researchers applied an untargeted approach that detected large numbers of spectral features defined by retention time and mass-to-charge ratio. In the retrospective cohort, they used targeted analytical platforms designed to quantify defined groups of amino acids and lipids, including nonesterified fatty acids, oxidized fatty acids, acylcarnitines, steroids, glycerophospholipids, sphingolipids, triglycerides, and cholesteryl esters. Samples were randomized, processed under controlled conditions, and analyzed without knowledge of clinical classification to reduce systematic bias. Statistical evaluation combined univariate tests with principal component analysis and supervised latent-variable methods. The principal component models assessed whether samples naturally clustered according to diagnosis or severity, whereas supervised orthogonal projection to latent structures and related discriminant methods maximized separation between predefined groups. The plots presented in Figure 1 on page 4 show partial separation between controls and patients, relapse-free and relapsing patients, and low- and high-disability groups, with the most substantial discriminatory performance observed for patients who reached higher EDSS levels during follow-up.
A Distinct Serum Metabolic Profile in Multiple Sclerosis
The study demonstrated that patients with MS possessed a serum metabolomic profile that differed from that of healthy controls. In the longitudinal cohort, 29 spectral peaks remained associated with MS across repeated measurements over the two-year period. Among the identifiable molecules, sphingomyelin and lysophosphatidylethanolamine emerged as particularly robust discriminators. Analysis of the larger cohort subsequently showed broader alterations involving amino acids, saturated and unsaturated fatty acids, diglycerols, triglycerides, cholesteryl esters, bile acids, steroids, lysophosphatidylcholines, phosphatidylinositols, ceramides, sphingomyelins, and monohexosylceramides. The heat map in Figure 2 on page 5 illustrates that these changes were not restricted to a single biochemical compound but extended across multiple interconnected lipid classes. This finding is biologically plausible because sphingolipids are major structural components of myelin, whereas phospholipids are essential constituents of cellular membranes, lipid rafts, intracellular signaling platforms, and proliferating immune cells. The observed signature may therefore reflect a composite of immune activation, membrane remodeling, glial responses, oxidative metabolism, and damage to lipid-rich neural tissue.
Metabolites Associated with Relapses and Disability Worsening
Several metabolites were associated specifically with clinical severity rather than merely with MS diagnosis. Relapse-free status was linked to differences in a diacylglycerophosphocholine species, arachidonic acid, 13S-hydroxyoctadecadienoic acid, and several lysophosphatidylcholine species. Disability progression was associated with hydrocortisone, glutamic acid, tryptophan, eicosapentaenoic acid, 13S-hydroxyoctadecadienoic acid, lysophosphatidylcholine 20:5, and lysophosphatidylethanolamine 20:5. These molecules span endocrine, inflammatory, neurotransmitter, and membrane-metabolic pathways. Glutamate is particularly relevant because it functions as the principal excitatory neurotransmitter in the central nervous system and, at excessive concentrations, can promote excitotoxic oligodendrocyte and neuronal injury. Tryptophan metabolism is also closely connected to immune regulation through enzymes such as indoleamine 2,3-dioxygenase, which can modify T-cell activation and inflammatory tolerance. Oxidized fatty acids and arachidonic-acid derivatives may reflect lipid peroxidation and inflammatory mediator production, while lysophospholipids can influence membrane signaling and immune-cell function. Table 2 on page 7 consolidates the metabolites associated with relapse-free status and EDSS worsening that were supported across the study cohorts.
Biological Interpretation: Phospholipid and Sphingolipid Imbalance
The authors interpret the findings primarily as evidence of altered phospholipid and sphingolipid homeostasis in MS. The pathway diagram in Figure 3 on page 6 places the detected metabolites within lipid biosynthesis, mitochondrial fatty-acid oxidation, glycerophospholipid metabolism, cholesterol processing, and sphingolipid production. Several nonexclusive mechanisms could generate this pattern. First, activated immune cells require extensive membrane synthesis and use phospholipids, sphingolipids, and fatty-acid derivatives as signaling mediators. Second, demyelination may release or redistribute myelin-associated lipids, particularly sphingolipids, into extracellular and systemic compartments. Third, reactive astrocytosis and microglial proliferation may increase phospholipid requirements and alter regional lipid composition. Sphingomyelin is especially significant because it is abundant in myelin and participates in sphingosine-1-phosphate signaling, a pathway with established relevance to lymphocyte trafficking and MS pharmacology. Phosphatidylethanolamine and phosphatidylcholine, meanwhile, contribute to membrane architecture, apoptotic signaling, vesicle formation, and immunoreceptor regulation. The metabolic abnormalities identified in serum should therefore be understood not as isolated laboratory findings but as possible systemic reflections of immune activation, oxidative stress, membrane turnover, and neuroglial injury.
Clinical Promise, Methodological Limitations, and Future Directions
Despite its scientific importance, the study should be regarded as an exploratory biomarker investigation rather than as evidence for an immediately deployable diagnostic test. The untargeted platform used in the prospective cohort detected spectral peaks that could not always be assigned to specific metabolites, limiting direct biological interpretation and preventing the construction of a fully standardized classifier across both cohorts. Treatment was another potential confounder, particularly because many participants received interferon-beta and changes in lysophosphatidylethanolamine were associated with disease-modifying therapy. Disease activity was defined clinically without systematic magnetic resonance imaging, meaning that patients with new asymptomatic lesions may have been incorrectly classified as stable. Furthermore, some predictive models demonstrated only moderate sensitivity or predictive accuracy, and multiple statistical comparisons increase the importance of independent replication. Nevertheless, the study established a credible framework for integrating longitudinal clinical phenotyping with high-dimensional metabolomic data. Future research should employ standardized targeted assays, larger external cohorts, MRI and neurofilament measurements, treatment-stratified analyses, and rigorous prospective validation. With such refinement, metabolomic panels could eventually complement conventional monitoring by identifying patients at increased risk of relapse or disability progression before irreversible neurological damage becomes clinically apparent.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Villoslada, P., Alonso, C., Agirrezabal, I., Kotelnikova, E., Zubizarreta, I., Pulido-Valdeolivas, I., ... & Castro, A. (2017). Metabolomic signatures associated with disease severity in multiple sclerosis. Neurology: Neuroimmunology & Neuroinflammation, 4(2), e321.
